Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study

Maki Hagihara, Noriyoshi Iriyama, Chikashi Yoshida, Hisashi Wakita, Shigeru Chiba, Shinichiro Okamoto, Kimihiro Kawakami, Naoki Takezako, Takashi Kumagai, Koiti Inokuchi, Kazuma Ohyashiki, Jun Taguchi, Shingo Yano, Tadahiko Igarashi, Yasuji Kouzai, Satoshi Morita, Junichi Sakamoto, Hisashi Sakamaki

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Despite the efficacy and safety of dasatinib treatment for chronic-phase chronic myeloid leukemia (CML-CP), adverse effects such as pleural effusion (PE) are still a serious concern. We determined the clinical significance of PE incidence using patient data derived from the D-First clinical study. In the present study, chest radiography and quantification of specific lymphocyte subsets were performed routinely after initiation of dasatinib treatment. Among 52 patients with newly diagnosed CML-CP, 17 (33%) developed PE within 18 months after initial dasatinib administration, but all cases were moderate (Grade 1, 10 patients; Grade 2, 7 patients). CD56+ lymphocyte counts at 1 month correlated significantly with the incidence of PE, whereas lymphocytosis did not. The major molecular response (MMR) rate at 3 months (although not at later times) was significantly higher in PE-positive patients than PE-negative patients (59% versus 24%, respectively; P=0.013). Deep molecular response rates did not differ significantly between the PE groups at any time point during the observation period. Our results suggest that an immunemediated mechanism involving natural killer cells underlies the development of PE in patients receiving dasatinib for 18 months. This mechanism likely promotes transient tumor regression in patients newly diagnosed with CML-CP.

Original languageEnglish
Pages (from-to)2976-2982
Number of pages7
JournalOncology Reports
Volume36
Issue number5
DOIs
Publication statusPublished - 2016 Nov 1

Fingerprint

Leukemia, Myeloid, Chronic Phase
Pleural Effusion
Lymphocytosis
Dasatinib
Incidence
Lymphocyte Subsets
Lymphocyte Count
Radiography
Natural Killer Cells
Thorax
Observation
Safety

Keywords

  • Chronic myeloid leukemia
  • Dasatinib
  • Molecular response
  • Newly-diagnosed
  • Pleural effusion

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib : Results of a D-First study. / Hagihara, Maki; Iriyama, Noriyoshi; Yoshida, Chikashi; Wakita, Hisashi; Chiba, Shigeru; Okamoto, Shinichiro; Kawakami, Kimihiro; Takezako, Naoki; Kumagai, Takashi; Inokuchi, Koiti; Ohyashiki, Kazuma; Taguchi, Jun; Yano, Shingo; Igarashi, Tadahiko; Kouzai, Yasuji; Morita, Satoshi; Sakamoto, Junichi; Sakamaki, Hisashi.

In: Oncology Reports, Vol. 36, No. 5, 01.11.2016, p. 2976-2982.

Research output: Contribution to journalArticle

Hagihara, M, Iriyama, N, Yoshida, C, Wakita, H, Chiba, S, Okamoto, S, Kawakami, K, Takezako, N, Kumagai, T, Inokuchi, K, Ohyashiki, K, Taguchi, J, Yano, S, Igarashi, T, Kouzai, Y, Morita, S, Sakamoto, J & Sakamaki, H 2016, 'Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study', Oncology Reports, vol. 36, no. 5, pp. 2976-2982. https://doi.org/10.3892/or.2016.5110
Hagihara, Maki ; Iriyama, Noriyoshi ; Yoshida, Chikashi ; Wakita, Hisashi ; Chiba, Shigeru ; Okamoto, Shinichiro ; Kawakami, Kimihiro ; Takezako, Naoki ; Kumagai, Takashi ; Inokuchi, Koiti ; Ohyashiki, Kazuma ; Taguchi, Jun ; Yano, Shingo ; Igarashi, Tadahiko ; Kouzai, Yasuji ; Morita, Satoshi ; Sakamoto, Junichi ; Sakamaki, Hisashi. / Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib : Results of a D-First study. In: Oncology Reports. 2016 ; Vol. 36, No. 5. pp. 2976-2982.
@article{5e1269d74f834f48bf6ed89684db6a2a,
title = "Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study",
abstract = "Despite the efficacy and safety of dasatinib treatment for chronic-phase chronic myeloid leukemia (CML-CP), adverse effects such as pleural effusion (PE) are still a serious concern. We determined the clinical significance of PE incidence using patient data derived from the D-First clinical study. In the present study, chest radiography and quantification of specific lymphocyte subsets were performed routinely after initiation of dasatinib treatment. Among 52 patients with newly diagnosed CML-CP, 17 (33{\%}) developed PE within 18 months after initial dasatinib administration, but all cases were moderate (Grade 1, 10 patients; Grade 2, 7 patients). CD56+ lymphocyte counts at 1 month correlated significantly with the incidence of PE, whereas lymphocytosis did not. The major molecular response (MMR) rate at 3 months (although not at later times) was significantly higher in PE-positive patients than PE-negative patients (59{\%} versus 24{\%}, respectively; P=0.013). Deep molecular response rates did not differ significantly between the PE groups at any time point during the observation period. Our results suggest that an immunemediated mechanism involving natural killer cells underlies the development of PE in patients receiving dasatinib for 18 months. This mechanism likely promotes transient tumor regression in patients newly diagnosed with CML-CP.",
keywords = "Chronic myeloid leukemia, Dasatinib, Molecular response, Newly-diagnosed, Pleural effusion",
author = "Maki Hagihara and Noriyoshi Iriyama and Chikashi Yoshida and Hisashi Wakita and Shigeru Chiba and Shinichiro Okamoto and Kimihiro Kawakami and Naoki Takezako and Takashi Kumagai and Koiti Inokuchi and Kazuma Ohyashiki and Jun Taguchi and Shingo Yano and Tadahiko Igarashi and Yasuji Kouzai and Satoshi Morita and Junichi Sakamoto and Hisashi Sakamaki",
year = "2016",
month = "11",
day = "1",
doi = "10.3892/or.2016.5110",
language = "English",
volume = "36",
pages = "2976--2982",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib

T2 - Results of a D-First study

AU - Hagihara, Maki

AU - Iriyama, Noriyoshi

AU - Yoshida, Chikashi

AU - Wakita, Hisashi

AU - Chiba, Shigeru

AU - Okamoto, Shinichiro

AU - Kawakami, Kimihiro

AU - Takezako, Naoki

AU - Kumagai, Takashi

AU - Inokuchi, Koiti

AU - Ohyashiki, Kazuma

AU - Taguchi, Jun

AU - Yano, Shingo

AU - Igarashi, Tadahiko

AU - Kouzai, Yasuji

AU - Morita, Satoshi

AU - Sakamoto, Junichi

AU - Sakamaki, Hisashi

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Despite the efficacy and safety of dasatinib treatment for chronic-phase chronic myeloid leukemia (CML-CP), adverse effects such as pleural effusion (PE) are still a serious concern. We determined the clinical significance of PE incidence using patient data derived from the D-First clinical study. In the present study, chest radiography and quantification of specific lymphocyte subsets were performed routinely after initiation of dasatinib treatment. Among 52 patients with newly diagnosed CML-CP, 17 (33%) developed PE within 18 months after initial dasatinib administration, but all cases were moderate (Grade 1, 10 patients; Grade 2, 7 patients). CD56+ lymphocyte counts at 1 month correlated significantly with the incidence of PE, whereas lymphocytosis did not. The major molecular response (MMR) rate at 3 months (although not at later times) was significantly higher in PE-positive patients than PE-negative patients (59% versus 24%, respectively; P=0.013). Deep molecular response rates did not differ significantly between the PE groups at any time point during the observation period. Our results suggest that an immunemediated mechanism involving natural killer cells underlies the development of PE in patients receiving dasatinib for 18 months. This mechanism likely promotes transient tumor regression in patients newly diagnosed with CML-CP.

AB - Despite the efficacy and safety of dasatinib treatment for chronic-phase chronic myeloid leukemia (CML-CP), adverse effects such as pleural effusion (PE) are still a serious concern. We determined the clinical significance of PE incidence using patient data derived from the D-First clinical study. In the present study, chest radiography and quantification of specific lymphocyte subsets were performed routinely after initiation of dasatinib treatment. Among 52 patients with newly diagnosed CML-CP, 17 (33%) developed PE within 18 months after initial dasatinib administration, but all cases were moderate (Grade 1, 10 patients; Grade 2, 7 patients). CD56+ lymphocyte counts at 1 month correlated significantly with the incidence of PE, whereas lymphocytosis did not. The major molecular response (MMR) rate at 3 months (although not at later times) was significantly higher in PE-positive patients than PE-negative patients (59% versus 24%, respectively; P=0.013). Deep molecular response rates did not differ significantly between the PE groups at any time point during the observation period. Our results suggest that an immunemediated mechanism involving natural killer cells underlies the development of PE in patients receiving dasatinib for 18 months. This mechanism likely promotes transient tumor regression in patients newly diagnosed with CML-CP.

KW - Chronic myeloid leukemia

KW - Dasatinib

KW - Molecular response

KW - Newly-diagnosed

KW - Pleural effusion

UR - http://www.scopus.com/inward/record.url?scp=84989814129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989814129&partnerID=8YFLogxK

U2 - 10.3892/or.2016.5110

DO - 10.3892/or.2016.5110

M3 - Article

C2 - 27665844

AN - SCOPUS:84989814129

VL - 36

SP - 2976

EP - 2982

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -